Clinical trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-12-16

PhasePHASE1

Study timeline

Study start (actual)2024-12-16Date precision: day

Registry last updated2026-10-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)unresolved

Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)unresolved

Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)unresolved

Metastatic Breast Cancerunresolved

Fulvestrantunresolved

Palazestrantunresolved

Interventions

FulvestrantDRUG · verified · RxNorm: fulvestrant

PalazestrantDRUG

Sponsors & collaborators

Olema Pharmaceuticals, Inc.lead sponsor

Mapped research locations

BostonMassachusetts, United States2 NashvilleTennessee, United States2 MadridMadrid, Spain2 New YorkNew York, United States1 San AntonioTexas, United States1 ColumbusOhio, United States1 AuroraColorado, United States1 New OrleansLouisiana, United States1 Grand RapidsMichigan, United States1 SarasotaFlorida, United States1 AdelaideSouth Australia, Australia1 BarcelonaBarcelona, Spain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06784193 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.